NeuroGenetic Pharmaceuticals

company

About

Neurogenetic Pharmaceuticals is engaged in the R&D of therapeutics for neurodegenerative disorders such as Alzheimer’s disease.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

Neurogenetic Pharmaceuticals, Inc. (NGP) is a biopharmaceutical discovery and development company founded in 2009 which is focused on developing innovative drug therapies for use in the treatment of neurodegenerative disorders such as Alzheimer’s disease. Based in San Diego, Calif., the company’s next objective is to obtain an Investigational New Drug approval for its clinical candidate, NGP 555. This compound is expected to prevent the deposition of amyloid plaques in the brain, thereby precluding neuronal cell death and the dementia associated with AD. Future clinical trials will utilize specific Αβ biomarkers and/or brain scanning as an early diagnostic and to monitor drug efficacy in clinical trials. NGP licensed the GSM intellectual property from TPTX and expanded its portfolio to include issued patents in the US, Europe, China, India, Japan, Australia, and other countries.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
NeuroGenetic Pharmaceuticals has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 4, 2012 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 4, 2012 Series Unknown 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
NeuroGenetic Pharmaceuticals is funded by 1 investors. Abbott Biotech Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Abbott Biotech Ventures Series Unknown